ISSN 1662-4009 (online)

ey0019.10-6 | New paradigms | ESPEYB19

10.6. Progression of type 1 diabetes from latency to symptomatic disease is predicted by distinct autoimmune trajectories

BC Kwon , V Anand , P Achenbach , JL Dunne , W Hagopian , J Hu , E Koski , AE Lernmark , M Lundgren , K Ng , J Toppari , R Veijola , BI Frohnert

T1DI Study Group. Nat Commun. 2022 Mar 21;13(1):1514. https://pubmed.ncbi.nlm.nih.gov/35314671/Brief Summary: This study of 5 birth cohorts of individuals at high risk for type 1 diabetes (T1D) used machine learning methods to explore trajectories from autoantibodies appearance to T1D progression. They identified 11 distinct latent health states and individuals progressed according to one o...

ey0020.8-4 | Important for Clinical Practice | ESPEYB20

8.4. Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study

M Ghalwash , JL Dunne , M Lundgren , M Rewers , AG Ziegler , V Anand , J Toppari , R Veijola , W Hagopian , Type 1 Diabetes Intelligence Study Group

Brief summary: Using data from the Type 1 Diabetes Intelligence (T1DI) cohort (n=24 662), this prospective study aimed to identify optimal ages for initial islet autoantibody (IAb) screening to predict the development of clinical type 1 diabetes (T1D). The identified optimal screening ages were 2 years and 6 years, with sensitivity of 82% and positive predictive value of 79% for T1D by age 15 years.Screening for T1D is a growing research topic a...

ey0018.10-13 | (1) | ESPEYB18

10.13. Type 1 diabetes can present before the age of 6 months and is characterized by autoimmunity and rapid loss of beta cells

MB Johnson , KA Patel , E De Franco , W Hagopian , M Killian , TJ McDonald , TIM Tree , C Domingo-Vila , M Hudson , S Hammersley , R; EXE-T1D Consortium Dobbs , S Ellard , SE Flanagan , AT Hattersley , RA Oram

Diabetologia. 2020;63(12):2605–2615. doi: 10.1007/s00125-020-05276-4.Diabetes diagnosed at <6 months of age is often of monogenic origin. However, 10-15% of affected infants do not have a pathogenic variant in one of the 26 known neonatal diabetes genes. In this study, 166 infants diagnosed at <6 months of age without such pathogenic variants showed all the the classic feat...

ey0019.10-2 | Reviews | ESPEYB19

10.2. Screening for type 1 diabetes in the general population: a status report and perspective

EK Sims , REJ Besser , C Dayan , Rasmussen C Geno , C Greenbaum , KJ Griffin , W Hagopian , M Knip , AE Long , F Martin , C Mathieu , M Rewers , AK Steck , JM Wentworth , SS Rich , O Kordonouri , AG Ziegler , KC Herold

NIDDK Type 1 Diabetes TrialNet Study Group.Diabetes. 2022 Apr 1;71(4):610-623. https://pubmed.ncbi.nlm.nih.gov/35316839/Brief Summary: This is a comprehensive review on general population screening, a current hot topic in the field of type 1 diabetes (T1D). The authors provide a critical overview of the rationale for population screening, arguments for and against it, current efforts to gui...